Foresee Pharmaceuticals Co Ltd (6576.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Taiwan · ISIN TW0006576002
Foresee Pharmaceuticals Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 418.69 m TWD | 431.27 m TWD |
| Gross profit | 239.80 m TWD | 294.22 m TWD |
| Operating income | -1.08 bn TWD | -862.32 m TWD |
| EBIT | -1.03 bn TWD | -852.64 m TWD |
| Net income | -1.08 bn TWD | -883.15 m TWD |
| Diluted EPS – continuing operations | -6.98 TWD | -5.61 TWD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.
More stocks
- Test Rite International Co Ltd (2908.TW)
- Securetech Innovations, Inc. (SCTH)
- Dezhou United Petroleum Technology Co.Ltd. (301158.SZ)
- Gaumont SA (GAM.PA)
- Stratec Se (SBS.DE)
- SFC Energy (F3C.DE)
- Focus Minerals Ltd (FML.AX)
- Dear U Co. Ltd. (376300.KQ)
- Shaanxi Meibang Pharmaceutical Group Co Ltd (605033.SS)
- AP Biosciences Inc (6945.TWO)
- Qinghai Spring Medicinal Resources Technology Co Ltd (600381.SS)
- K-Bro Linen Inc. (KBL.TO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.